Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis

Emma E van Daalen; Raffaella Rizzo; Andreas Kronbichler; Ron Wolterbeek; Jan A Bruijn; David R Jayne; Ingeborg M Bajema; Chinar Rahmattulla

doi:10.1136/annrheumdis-2016-209925

Article info

Clinical and epidemiological research

Extended report

Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis

Authors

Emma E van Daalen Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands PubMed articles Google scholar articles
Raffaella Rizzo Nephrology, Dialysis and Hypertension Unit, St Orsola-Malpighi University Hospital, Bologna, Italy Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK PubMed articles Google scholar articles
Andreas Kronbichler Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK Department of Internal Medicine IV (Nephrology and Hypertension), Medical University of Innsbruck, Innsbruck, Austria PubMed articles Google scholar articles
Ron Wolterbeek Department of Medical Statistics and Bioinformatics, Leiden University Medical Centre, Leiden, The Netherlands PubMed articles Google scholar articles
Jan A Bruijn Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands PubMed articles Google scholar articles
David R Jayne Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK PubMed articles Google scholar articles
Ingeborg M Bajema Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands PubMed articles Google scholar articles
Chinar Rahmattulla Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK PubMed articles Google scholar articles

Correspondence to Emma Elisabeth van Daalen, Department of Pathology, L1-Q (P0-107), Leiden University Medical Centre, P.O. Box 9600, Leiden 2300 RC, The Netherlands; E.E.van_Daalen{at}lumc.nl

View Full Text

Citation

van Daalen EE, Rizzo R, Kronbichler A, et al

Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis

Annals of the Rheumatic Diseases 2017;76:1064-1069.

Publication history

Received May 20, 2016
Revised November 10, 2016
Accepted November 12, 2016
First published November 29, 2016.

Online issue publication

April 11, 2023

Article Versions

Previous version (2 November 2019).
You are viewing the most recent version of this article.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password